Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 and Cetuximab in KRAS G12D Mutant Metastatic Colorectal Cancer
NCT07913360Phase 3Not yet recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Nov 2026
- Primary completion
- Nov 2028
01
Overview
A Phase 3 trial of GFH375 in colorectal cancer (CRC), sponsored by GenFleet Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
GFH375
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07913360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913360.